Furthermore, MASLD, a hepatic manifestation of metabolic syndrome, is strongly associated with systemic insulin resistance, and compensatory hyperinsulinemia and insulin signaling may induce HCC via various carcinogenic pathways [65]. Here, INS is linked to hepatocellular carcinoma.